Synthesis of eugenol esters derivatives as breast cancer drugs Available to Purchase

The abudance of natural compounds such as eugenol from clove essential oil has shown anticancer ability. Interestingly, the modification of the structure of the eugenol ester derivative compound fused with other essential oil compounds has a better ability as an anticancer. The screening in-silico studies were used to see the effectiveness and efficiency of the compounds as breast cancer drug candidates by comparing with the doxorubicin cancer drug standard, 16 eugenol ester derivatives docked against five cancer proteins as representatives of breast cancer such as MMP9, MMP2, Cyclin A2 (CCNA2), BAK, and P53. The best compounds for screening will be synthesized with steglich esterification using DCC and DMAP catalysts. The in-silico screening result showed eugenyl salicylate and isoeugenyl salicylate have the best binding affinity values of -8.5 and -8.9 kcal/ mol in MMP9. The synthesis result of eugenyl salicylate and isoeugenyl salicylate shows the Rf value of TLC with eluent n-hexane: ethyl acetate (9:1) is 0.58, whereas LCMS results for each compound showed yield values of 48.32% (RT: 10.79) and 59.85% (RT: 9.67).